Inactive Instrument

PCAS Stock

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

10/02/24	Orapi: takeover bid reopens on February 12
03/02/24	Orapi: 3.15 million shares tendered to the takeover bid
23/12/23	Orapi: takeover bid opens on December 27
19/12/23	PCAS: 200 ME capital increase
04/11/23	PCAS: OPAS to start this Friday
25/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
17/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
06/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/06/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

25/10/23	PCAS: Net Sales as of September 30, 2023	GL
07/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
28/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
03/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

10/02/24	Orapi : l'OPA réouvre le 12 février
03/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
23/12/23	Orapi : l'OPA démarre le 27 décembre
19/12/23	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news: PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+3.10%	-1.58%	+43.66%	+134.84%	1,206B
JOHNSON & JOHNSON	+0.24%	+2.21%	+46.77%	+87.58%	665B
ABBVIE INC.	-0.28%	+0.32%	+32.49%	+109.92%	515B
ROCHE HOLDING AG	+2.65%	+0.78%	+43.53%	+68.12%	381B
MERCK & CO., INC.	+0.19%	-0.94%	+69.41%	+43.54%	362B
NOVARTIS AG	+0.11%	+1.17%	+30.20%	+57.84%	307B
ASTRAZENECA PLC	+0.98%	+1.15%	+6.81%	+34.34%	289B
AMGEN INC.	-0.51%	-1.76%	+41.27%	+73.16%	249B
GILEAD SCIENCES, INC.	+0.72%	-1.67%	+41.76%	+123.38%	207B
Average	+0.81%	-1.54%	+39.54%	+81.41%	464.42B
Weighted average by Cap.	+1.33%	-1.96%	+41.22%	+93.44%